Stanford University School of Medicine–led researchers have found that intensive blood pressure (BP) control produces ...

Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised ...

Smoking behavior seems to not have a causal effect on chronic kidney disease (CKD) risk in White individuals, according to a ...

Chronic kidney disease (CKD) is an umbrella term used to describe a longstanding disease or condition that causes the progressive loss of kidney (renal) function. Symptoms vary, depending on the stage ...

As a chronic condition, kidney failure is the final stage of chronic kidney disease. Medical professionals also refer to it as end stage renal disease (ESRD) or end stage kidney disease (ESKD).

HealthDay News — Gestational exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk for childhood chronic kidney disease (CHD), although the association is not ...

Kidney transplantation represents a significant advancement for managing end-stage renal disease (ESRD), offering improved recipient quality of life and ...

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies ...

even in advanced chronic kidney disease; cysts derived from proximal tubules, but not those derived from distal tubules, contained increased concentrations of bioactive erythropoietin.

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.

Some people, however, may develop the progressive loss of kidney function, or chronic kidney disease (CKD). High blood pressure may be a sign of kidney dysfunction. It can damage the blood vessels ...